Pharmacological options in the treatment of benign prostatic hyperplasia

Journal of Medicinal Chemistry

Volumn 40, Issue 9, 1997, Pages 1293-1315

  Kenny, Barry ^a   Ballard, Stephen ^a   Blagg, Julian ^a   Fox, David ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 AMIDE 5 [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 2 (2 AMINOETHOXYMETHYL) 6 ETHYL 1,4 DIHYDRO 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 AMIDE 3 [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; 3 [N [2 (4 HYDROXY 2 ISOPROPYL 5 METHYLPHENOXY)ETHYL] N METHYLAMINOMETHYL] 4 METHOXY 2,5,6 TRIMETHYLPHENOL; 4 [2 [4 (4 ISOBUTYL ALPHA METHYLBENZYLOXY) 2,3 DIMETHYLBENZAMIDO]PHENOXY]BUTYRIC ACID; 4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 5 METHYLURAPIDIL; 7 CHLORO 3,4,5,6 TETRAHYDRO 4 METHYL 2 VINYLTHIENO[4,3,2 EF][3]BENZAZEPINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; 8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLAZOSIN; DOXAZOSIN; FINASTERIDE; GG 818; INDORAMIN; NIGULDIPINE; PRAZOSIN; QUINAZOLINE DERIVATIVE; SILODOSIN; SL 890591; SNAP 1069; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; PROSTATE HYPERTROPHY; REVIEW; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CONTROLLED CLINICAL TRIALS; ENDOTHELINS; ENZYME INHIBITORS; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0030913442     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960697s     Document Type: Review

References (158)

1. Kirby, R.; Christmas, T. Epidemiology and natural history. In Benign Prostatic Hyperplasia; Kirby, R., Christmas, T., Eds.; Gower Medical Publishing: London, England, 1993.
2. McNeal, J. E. Origin and evolution of benign prostatic hyperplasic enlargement. Invet. Urol. 1978, 15, 340-345.
3. McNeal, J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol. Clin. North Am. 1990, 17, 477-486.
4. Steers, W. D.; Zorn, B. Benign prostatic hyperplasia. Disease Month 1995, 41, 437-500.
5. Bartsch, G.; Muller, H. R.; Oberholzer, M.; Rohr, H. P. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J. Urol. 1979, 122, 487-491.
6. Furuya, S.; Kumamoto, Y.; Yokoyama, E.; Tsukamoto, T.; Izumi, T.; Abiko, Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. 1982, 128, 836-839.
7. White, J. W. The results of double castration in hypertrophy of the prostate. Ann. Surg. 1895, 22, 1-80.
8. Moore, R. A. Benign hyperthrophy and carcinoma of the prostate. Occurrence and experimental production in animals. Surgery 1944, 16, 152-167.
9. McConnell, J. D.; Wilson, J. D.; George, F. W.; Geller, J.; Pappas, F.; Stoner, E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 1992, 74, 505-508.
10. Geller, J. Overview of benign prostatic hyperplasia. Urology (Suppl.) 1989, 34, 57-63.
11. McConnell, J. D. Other hormonal treatments. In Textbook of Benign Prostatic Hyperplasia; Kirby, R., McConnell, J., Fitzpatrick, J., Roehrborn, C., Boyle, P., Eds.; Isis Medical Media: Oxford, 1996; pp 271-277.
12. Imperato-McGinley, J. I.; Guerro, L.; Gautier, T.; Peterson, R. E. Steroid 5α-reductase defficiency in man: an inherited form of male pseudohermaphroditism. Science 1977, 1213-1225.
13. Imperato-McGinley, J. I.; Gautier, T.; Zirinsky, K.; Hom, T.; Palomo, O.; Stein, E.; Vaughan, E. D.; Markisz, J. A.; Ramirez de Arellano, E.; Kazam, E. Prostate visualization studies in males homozygous and heterozygous for 5α-reductase defficiency. J. Clin. Endocrinol. 1992, 75, 1022-1026.
14. Wilson, J. D.; Griffin, J. E.; Russell, D. W. Steroid 5α-reductase 2 defficiency. Endocr. Rev. 1993, 14, 577-593.
15. Russell, D. W.; Wilson, J. D. Steroid 5α-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994, 63, 25-61.
16. Andersson, S.; Berman, D. M.; Jenkins, E. P.; Russell, D. W. Deletion of steroid 5α reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354, 159-161.
17. Normington, K.; Russell, D. W. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes. J. Biol. Chem. 1992, 267, 19548-19554.
18. Berman, D. M.; Russell, D. W. Cell-type-specific expression of rat steroid 5α-reductase isozymes. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9359-9363.
19. Bonnet, P.; Reiter, E.; Bruyninx, M.; Sente, B.; Dombrowicz, D.; de Leval, J.; Closset, J.; Hennen, G. Benign prostatic hyperplasia and normal prostate aging; differences in type I and type II 5α-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not insulin-like growth factor mRNA levels. J. Clin. Endocrinol. Metab. 1993, 77, 1203-1208.
20. Span, P. N.; Benraad, Th. J.; Sweep, C. G. J.; Smals, G. H. Kinetic analysis of steroid 5α-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate. J. Steroid Biochem. Mol. Biol. 1996, 57, 103-108.
21. McConnell, J. D. Prostatic growth: new insights into hormonal regulation. Br. J. Urol. (Suppl.) 1995, 1, 5-10.
22. Culig, Z.; Hobisch, A.; Cronauer, M. V.; Radmayr, C.; Hittmair, A.; Zhang, J.; Thurnher, M.; Bartsch, G.; Klocker, H. Regulation of prostatic growth factors and function by peptide growth factors. Prostate 1996, 28, 392-405.
23. Wang, J.; McKenna, K.; McVary, K.; Lee, C. Requirement of innervation for maintainance of structural and functional integrity in the rat prostate. Biol. Reprod. 1991, 44, 1171-1176.
24. Dixon, J. S.; Gosling, J. A. Microanatomy of the prostate. In Textbook of Benign Prostatic Hyperplasia; Kirby, R., McConnell, J., Fitzpatrick, J., Roehrborn, C., Boyle, P., Eds.; Isis Medical Media: Oxford, 1996; pp 3-10.
25. Chapple, C. R.; Aubrey, M. L.; James, S.; Greengrass, P. M.; Burnstock, G.; Turner-Warwick, R. T.; Milroy, E. J.; Davey, M. J, Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br. J. Urol. 1989, 63, 487-496.
26. 1 adrenoceptors in different regions of the human prostate. J. Urol. 1993, 150, 252-256.
27. Hieble, J. P.; Bylund, D. B.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, R. R., Jr. International Union of Pharmacology X. Recommendation for nomenclature of alpha-1 adrenoceptors: Consensus Update. Pharmacol. Rev. 1995, 47, 267-270.
28. 1 adrenergic subtypes in human prostate. J. Urol. 1993, 150, 546-551.
29. 1C-adrenoceptor splice variants. FEBS Lett. 1995, 363, 256-260.
30. 1c-adrenoceptor in human prostate: cloning, functional expression, and localization to specific cell types. Br. J. Pharmacol. 1995, 115, 1475-1485.
31. 1 adrenoceptor subtypes present in the human prostate. Life Sci. 1994, 54, 1595-1605.
32. Hieble, J. P.; Caine, M.; Zalaznik, E. In vitro characterisation of alpha adrenoceptors in human prostate. Eur. J. Pharmacol. 1985, 107, 111-117.
33. Chueh, S.; Guh, J.; Chen, J.; Lai, M.; Ko, F.; Teng, C. Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur. J. Pharmacol. 1996, 305, 177-180.
34. Yamada, S.; Ashizawa, N.; Ushijima, H.; Nakayama, K.; Hayashi, E.; Honda, K. Alpha-1 adrenoceptors in human prostate: characterizations and alteration in benign prostatic hypertrophy. J. Pharmacol. Exp. Ther. 1987, 242, 326-330.
35. Kenny, B. A.; Naylor, A. M.; Wyllie, M. G. Prostatic adrenoceptors. In Textbook of Benign Prostatic Hyperplasia; Kirby, R., McConnell, J., Fitzpatrick, J., Roehrborn, C., Boyle, P., Eds.; Isis Medical Media: Oxford, 1996; pp 75-84.
36. Kitada, S.; Kumazawa, J. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J. Urol. 1987, 138, 158-160.
37. Shapiro, E.; Hartanto, V.; Lepor, H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992, 21, 297-307.
38. 1c-)adrenoceptor subtype. Br. J. Pharmacol. 1995, 115, 781-786.
39. 1c subtype. Mol. Pharmacol. 1994, 45, 703-708.
40. Goetz, A. S.; Lutz, M. W.; Rimele, T. J.; Saussy, D. L. Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes. J. Pharmacol. Exp. Ther. 1994, 271, 1228-1233.
41. 1 adrenoceptor subtypes in the human prostate; functional and binding studies. Br. J. Urol. 1994, 74, 572-578.
42. Ford, A. P. D. W.; Arredondo, N. F.; Blue, D. R., Jr.; Bonhaus, D. W.; Kava, M. S.; Williams, T. J.; Vimont, R. L.; Zhu, Q. M.; Pfister, J. R.; Clarke, D. E. Do alpha-1A (alpha-1C) -adrenoceptors (AR) mediate prostatic smooth muscle contraction in man? Studies with a novel, selective alpha-1A-AR antagonist, RS 17053. Br. J. Pharmacol. 1995, 114, 24P.
43. 2+ channel antagonist niguldipine. J. Med. Chem. 1995, 38, 1579-1581.
44. 1 adrenoceptors in human prostate: implications for classification. Mol. Pharmacol. 1996, 49, 209-215.
45. 1L AR subtype. ICS Meeting, Athens, Greece, August 1996.
46. Williams, T. J.; Ford, A. P. D. W. Whole cell radioligand binding assay reveals a1L-adrenoceptor (AR) anatgonist profile for the human cloned a1A-AR in Chinese hamster overy (CHO-K1) cells. Br. J. Pharmacol. 1996, 52.
47. Kenny, B. A.; Naylor, A. M.; Carter, A. J.; Read, A. M.; Greengrass, P. M.; Wyllie, M. G. Effect of alpha-1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anaesthetised dog. Urology 1994, 44, 52-57.
48. 1 adrenoceptor antagonist in the lower urinary tract. Br. J. Pharmacol. 1993, 109, 1282-1289.
49. 1 adrenoceptor antagonist selective for the lower urinary tract: In vivo studies. Neurourol. Urodyn. 1994, 13, 471-472
50. Shibasaki, M.; Sudoh, K.; Inagaki, O.; Uchida, W.; Honda, K. Effect of the optical isomers of YM-12617 on increased intraurethral pressure induced by phenylephrine in anaesthetised dogs. J. Auton. Pharmacol. 1992, 12, 263-268.
51. 1-AR) antagonists in dog prostate/ blood pressure models. Faseb J. 1996, 10, A425.
52. Brune, M. E.; Buckner, S. A.; Polakowski, J.; Kerwin, J. F.; Hancock, A. Pharmacological antagonism of α adrenergic agonist induced increases in canine intraurethral pressure in vivo. Drug Dev. Res. 1995, 34, 267-275.
53. Katwala, S. P.; Milicic, I. P.; Hancock, A. A.; Kerwin, J. P.; Brune, M. E. Differential effects of various alpha-1 adrenoceptor antagonists on urogenital and vascular smooth muscle in vivo. Faseb J. 1996, 10, A425.
54. 1 adrenoceptors: binding, functional and in vivo studies. Br. J. Pharmacol. 1996, 118, 871-878.
55. Testa, R.; Guarneri, L.; Taddei, C.; Poggesi, E.; Angelico, P.; Sartani, A.; Leonardi, A.; Gofrit, O. N.; Meretyk, S.; Caine, M. Functional antagonistic activity of Rec 15/2739, a novel alpha 1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J. Pharmacol. Exp. Ther. 1996, 277, 1237-1246.
56. 1A/L adrenoceptor antagonist, RS-100975. Neurourol. Urodyn. 1996, 14, 345-346.
57. Shaffer, J.; Saussy, D. Personal communication, with permission, 1996.
58. Vargas, H. M.; Gorman, A. J. Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci. 1995, 57, 2291-2308.
59. Kenny, B. A.; Chalmers, D. H.; Philpott, P. C.; Naylor, A. M. Characterisation of an am adrenoceptors mediating the contractile response of rat aorta to noradrenaline. Br. J. Pharmacol. 1995, 115, 981-986.
60. 1c-Adrenergic antagonists and orthostatic hypotension in the rat. Faseb J. 1994, 8, A353.
61. Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D.; Bergsma, D.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R., Jr.; Leonardi, A. REC 15/2739 (SB216469): A novel prostate selective alpha-1 adrenoceptor antagonist. Pharmacol. Commun. 1995, 6, 79-86.
62. Kyncl, J. J.; Horrom, B. W. R(+)-Terazosin. International Patent Application No. WO 92/00073, Jan. 9, 1992.
63. Leonardi, A.; Motta, G.; Boi, C.; Testa, R. Quinazolinyl-amino derivatives having α-antagonist activity. International Patent Application No. WO 95/25726, Sept. 28, 1995.
64. 1-Adrenoceptors: subtype-and organ-selectivity of different agents. 10th Camerino-Noordwijkerhout Symposium on Perspectives in Receptor Research, Sept. 10-14, 1995.
65. Archibald, J. L.; Alps, B. J.; Cavalla, J. F.; Jackson, J. L. Synthesis and hypotensive activity of benzamidopiperidylethylindoles. J. Med. Chem. 1971, 14, 1054-1059.
66. 2+ channel antagonist niguldipine. J. Med. Chem. 1995, 38, 1579-1581.
67. (b) Gluchowski, C.; Wetzel, J. M.; Chiu, G.; Marzabadi, M. R.; Wong, W. C.; Nagarathnam, D. Dihydropyridines and new uses thereof. International Patent Application No. WO 94/22829, Oct. 13, 1994.
68. Marzabadi, M. R. Design and synthesis of novel dihydropyridine alpha-1a antagonist. ACS National Meeting, New Orleans, LA, March 24-28, 1996.
69. Huff, J. R.; Lee, H.-Y.; Nerenberg, J. B.; Thompson, W. J. Alpha 1c adrenergic receptor antagonists. International Patent Application No. WO 95/28397, Oct. 26, 1995.
70. 1-adrenoceptor antagonists. 13th International Symposium on Medicinal Chemistry, Paris, France, Sept. 19-23, 1994.
71. 1-adrenoceptor antagonist. 13th International Symposium on Medicinal Chemistry, Paris, France, Sept. 19-23, 1994.
72. 1A-antagonists. International Patent Application No. WO 95/ 04049, Feb. 9, 1995.
73. 1-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. 13th International Symposium on Medicinal Chemistry, Paris, France, Sept. 19-23, 1994.
74. Clarke, D. E.; Elworthy, T. R.; Morgans, D. J., Jr.; Pfister, J. R.; Repke, D. B.; Sjogren, E. B.; Wu, H. Y.-H. 3-(4-Phenylpiperazin-1-yl)propyl-amino, thio and oxy-pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists. International Patent Application No. EP 0711757, May 15, 1996.
75. 1-adrenoceptors and native tissues. Mol. Pharmacol. 1995, 48, 250-258.
76. Chiu, G.; Gluchowski, C. Novel aromatic amine derivatives. International Patent Application No. WO 95/07075, March 16, 1995.
77. 1-adrenoceptor antagonist, JHT-601: comparison with prazosin. Eur. J. Pharmacol. 1996, 300, 155-157.
78. Andrews, R. C.; Brown, P. J.; Cadilla, R.; Drewry, D. H.; Luzzio, M. J.; Marron, B. E. Oxazole derivatives as antagonists of α-1C adrenergic receptors. International Patent Application No. WO 96/16049, May 30, 1996.
79. Frye, S. V. Inhibitors of 5α-Reductase. Curr. Pharm. Des. 1996, 2, 59-84.
80. Abell, A. D.; Henderson, B. R. Steroidal and non-steroidal inhibitors of steroid 5α-reductase. Curr. Med. Chem. 1995, 2, 583-597.
81. Levy, M. A.; Brandt, M.; Greway, A. T. Mechanistic studies with solubifised rat liver steroid 5α-reductase: elucidation of the kinetic mechanism. Biochemistry 1990, 29, 2808-2815.
82. Levy, M. A.; Brandt, M.; Keys, J. R.; Holt, D. A.; Metcalf, B. W. Inhibition of rat liver steroid 5α-reductase by 3-androstene-3-carhoxylic acids; mechanism of enzyme-inhibitor interaction. Biochemistry 1990, 29, 2815-2824.
83. Rasmusson, G. H.; Johnston, D. B. R.; Reinhold, D. F.; Utne, T.; Jobson, R. B. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors. International Patent Application U.S. 4,220,775, Sept. 2, 1980. Rasmusson, G. H.; Johnston, D. B. R.; Arth, G. E. 4-Aza-17β-substituted 5α-androstan-3-one reductase inhibitors. International Patent Application U.S. 4,377,584, March 22, 1983.
84. Rasmusson, G. H.; Johnston, D. B. R.; Reinhold, D. F.; Utne, T.; Jobson, R. B. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors. International Patent Application U.S. 4,220,775, Sept. 2, 1980. Rasmusson, G. H.; Johnston, D. B. R.; Arth, G. E. 4-Aza-17β-substituted 5α-androstan-3-one reductase inhibitors. International Patent Application U.S. 4,377,584, March 22, 1983.
85. Andersson, S.; Russell, D. W. Steroid 5α-reductases. International Patent Application WO 91/17251, Nov. 14, 1991. Andersson, S.; Russell, D. W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 3640. Andersson, S.; Berman, D. M.; Russell, D. W.; Jenkins, E. P. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354, 159. Jenkins, E. P.; Andersson, S.; Imperato-McGinley, J. I.; Wilson, J. D.; Russell, D. W. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J. Clin. Invest. 1992, 89, 293.
86. Andersson, S.; Russell, D. W. Steroid 5α-reductases. International Patent Application WO 91/17251, Nov. 14, 1991. Andersson, S.; Russell, D. W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 3640. Andersson, S.; Berman, D. M.; Russell, D. W.; Jenkins, E. P. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354, 159. Jenkins, E. P.; Andersson, S.; Imperato-McGinley, J. I.; Wilson, J. D.; Russell, D. W. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J. Clin. Invest. 1992, 89, 293.
87. Andersson, S.; Russell, D. W. Steroid 5α-reductases. International Patent Application WO 91/17251, Nov. 14, 1991. Andersson, S.; Russell, D. W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 3640. Andersson, S.; Berman, D. M.; Russell, D. W.; Jenkins, E. P. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354, 159. Jenkins, E. P.; Andersson, S.; Imperato-McGinley, J. I.; Wilson, J. D.; Russell, D. W. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J. Clin. Invest. 1992, 89, 293.
88. Andersson, S.; Russell, D. W. Steroid 5α-reductases. International Patent Application WO 91/17251, Nov. 14, 1991. Andersson, S.; Russell, D. W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 3640. Andersson, S.; Berman, D. M.; Russell, D. W.; Jenkins, E. P. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354, 159. Jenkins, E. P.; Andersson, S.; Imperato-McGinley, J. I.; Wilson, J. D.; Russell, D. W. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J. Clin. Invest. 1992, 89, 293.
89. Rasmusson, G. H.; Reynolds, G. F.; Utne, T.; Jobson, R. B.; Primka, R. L.; Berman, C.; Brooks, J. R. Azasteroids as Inhibitors of Rat Prostatic 5α-Reductase. J. Med. Chem. 1984, 27, 1690-1701. Rasmusson, G. H.; Reynolds, G. P.; Steinberg, N. G.; Walton, E.; Patel, C. F.; Lia, T.; Cascieri, M. A.; Cheung, A. H.; Berman, C.; Brooks, J. R. Azasteriods: Structure-Activity Relationships for Inhibition of 5α-Reductase and of Androgen Receptor Binding. J. Med. Chem. 1986, 29, 2298-2315.
90. Rasmusson, G. H.; Reynolds, G. F.; Utne, T.; Jobson, R. B.; Primka, R. L.; Berman, C.; Brooks, J. R. Azasteroids as Inhibitors of Rat Prostatic 5α-Reductase. J. Med. Chem. 1984, 27, 1690-1701. Rasmusson, G. H.; Reynolds, G. P.; Steinberg, N. G.; Walton, E.; Patel, C. F.; Lia, T.; Cascieri, M. A.; Cheung, A. H.; Berman, C.; Brooks, J. R. Azasteriods: Structure-Activity Relationships for Inhibition of 5α-Reductase and of Androgen Receptor Binding. J. Med. Chem. 1986, 29, 2298-2315.
91. Bull, H. G. Mechanism-Based Inhibition of Human Steriod 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. J. Am. Chem. Soc. 1996, 118, 2359-2365.
92. Kurata, H.; Horikoshi, H.; Hamada, T. Azasteroid Compounds for the Treatment of Benign Prostatic Hypertrophy, their Preparation and Use. International Patent Application EP 484,-094, May 6, 1992. Biollaz, M. Neue 17-beta-substituierte-Aza-androstan-derivate. International Patent Application EP-538 192, April 21, 1993. Labrie, F.; Merand, Y. M.; Singh, S. M. Inhibitors of Testosterone 5α-Reductase Activity. International Patent Application WO-93/23053, Nov. 25, 1993.
93. Kurata, H.; Horikoshi, H.; Hamada, T. Azasteroid Compounds for the Treatment of Benign Prostatic Hypertrophy, their Preparation and Use. International Patent Application EP 484,-094, May 6, 1992. Biollaz, M. Neue 17-beta-substituierte-Aza-androstan-derivate. International Patent Application EP-538 192, April 21, 1993. Labrie, F.; Merand, Y. M.; Singh, S. M. Inhibitors of Testosterone 5α-Reductase Activity. International Patent Application WO-93/23053, Nov. 25, 1993.
94. Kurata, H.; Horikoshi, H.; Hamada, T. Azasteroid Compounds for the Treatment of Benign Prostatic Hypertrophy, their Preparation and Use. International Patent Application EP 484,-094, May 6, 1992. Biollaz, M. Neue 17-beta-substituierte-Aza-androstan-derivate. International Patent Application EP-538 192, April 21, 1993. Labrie, F.; Merand, Y. M.; Singh, S. M. Inhibitors of Testosterone 5α-Reductase Activity. International Patent Application WO-93/23053, Nov. 25, 1993.
95. Li, X.; Singh, S. M.; Cote, J.; Laplante, S.; Vielleux, R.; Labrie, F. Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17β-carboxamides as 5α-Reductase Inhibitors and Antiandrogens. J. Med. Chem. 1995, 38, 1456-1461.
96. Haasae-Held, M.; Hatzis, M.; Mann, J. The Synthesis of 4-Cyano-progesterone: a potent inhibitor of the enzyme 5α-Reductase. J. Chem. Soc., Perkin Trans. I 1992, 2999-3000.
97. McConnell, J. D. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. 1990, 17, 661-670.
98. 5-isomerase from bovine adrenals: mechanism of inhibition by 3-oxo-4-aza steroids and kinetic mechanism of the dehydrogenase. Biochemistry 1989, 28, 140.
99. 5-isomerase from bovine adrenals: mechanism of inhibition by 3-oxo-4-aza steroids and kinetic mechanism of the dehydrogenase. Biochemistry 1989, 28, 140.
100. Steiner, J. F. Clinical Pharmacokinetics and Pharmacodynamics of Finasteride. Clin. Pharmacokinet. 1996, 30, 16-27.
101. Lepor, H.; Williford, W. O.; Barry, M. J.; Brawer, M. K.; Dixon, C.; Gormley, G.; Haakenson, C.; Machi, M.; Narayan, P.; Padley, R. J. The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia. N. Engl. J. Med. 1996, 335, 533-538.
102. Bakshi, R. K.; Rasmusson, G. H.; Patel, G. H.; Mosely, R. T.; Chang, B.; Ellsworth, K.; Harris, G. S.; Tolman, R. L. 4-Aza-3-oxo-5α-androst-1-ene-17β-N-aryl-carboximides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5α-Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5α-Reductase Inhibitory Potency. J. Med. Chem. 1995, 38, 3189-3192.
103. 1-4-Azasteroids: Toward Perfection of Rates of Time-Dependent Inhibition by Using Ligand-Binding Energies. Biochemistry 1995, 34, 13453-13459.
104. Di Salle, E.; Briatico, G.; Giudici, D.; Ornati, G.; Nesi, M.; Panzeri, A. 17β-Acylurea Derivatives of 4-Azasteroids as Inhibitors of Testosterone 5α-Reductase. J. Steroid Biochem. Mol. Biol. 1992, 41, 765-768.
105. Di Salle, E.; Briatico, G.; Giudici, D.; Ornati, G.; Panzeri, A. Endocrine Properties of the Testosterone 5α-Reductase Inhibitor Turosteride (FCE 26073). J. Steroid Biochem. Mol. Biol. 1994, 48, 241-248.
106. Moss, M. L.; Kuzmic, J. P.; Stuart, D.; Tian, G.; Peranteau, A. G.; Frye, S. V.; Kadwell, S. H.; Kost, T. A.; Overton, L. K.; Patel, I. R. Inhibition of Human Steroid 5α-Reductases type I and II by 6-Aza-Steriods: Structural Determinants of One-Step vs Two-Step Mechanism. Biochemistry 1996, 35, 3457-3464.
107. 5-steroid Isomerase. J. Med. Chem. 1994, 37, 2352-2360.
108. 5-steroid Isomerase by 6-Aza-androst-4-en-3-ones: Optimization of the C17 Substituent. J. Med. Chem. 1995, 38, 2621-2627.
109. Holt, D. A.; Levy, M. A.; Oh, H.-J.; Erb, J. M.; Heaslip, J. I.; Brandt, M.; Lan-Hargest, H.-Y.; Metcalf, B. W. Inhibition of Steroid 5α-Reductase by Unsaturated 3-Carboxysteroids. J. Med. Chem. 1990, 33, 943-950.
110. Levy, M. A.; Brandt, M.; Sheedy, K. M.; Dinh, J. T.; Holt, D. A.; Garrison, L. M.; Bergsma, D. J.; Metcalf, B. W. Epristeride is a Selective and Specific Uncompetitive Inhibitor of Human Steroid 5α-Reductase Isoform 2. J. Steroid Biochem. Mol. Biol. 1994, 48, 197-206.
111. Audet, P.; Nurcombe, H.; Lamb, Y.; Jorkasky, D.; Loyd-Davies, K.; Morris, R. Effect of Multiple Doses of Epristeride (E) a Steroidal 5α-Reductase Inhibitor on Serum Dihydrotestosterone (DHT) in Older Male Subjects. Clin. Pharmacol. Ther. 1993, 53, 231. Chapelsky, M. C.; Nichols, A.; Jorkasky, D. K.; Lundberg, D. E.; Knox, S. H.; Audet, P. R. Pharmacodynamics of SK&f 105657 in Healthy Male Subjects. Clin. Pharmacol. Ther. 1992, 51, 154.
112. Audet, P.; Nurcombe, H.; Lamb, Y.; Jorkasky, D.; Loyd-Davies, K.; Morris, R. Effect of Multiple Doses of Epristeride (E) a Steroidal 5α-Reductase Inhibitor on Serum Dihydrotestosterone (DHT) in Older Male Subjects. Clin. Pharmacol. Ther. 1993, 53, 231. Chapelsky, M. C.; Nichols, A.; Jorkasky, D. K.; Lundberg, D. E.; Knox, S. H.; Audet, P. R. Pharmacodynamics of SK&f 105657 in Healthy Male Subjects. Clin. Pharmacol. Ther. 1992, 51, 154.
113. Holt, D. A.; Levy, M. A.; Ladd, D. L.; Oh, H.-J.; Erb, J. M.; Heaslip, J. I.; Brandt, M.; Metcalf, B. W. Steroidal A Ring Aryl Carboxylic Acids: A New Class of Steroidal 5α-Reductase Inhibitors. J. Med. Chem. 1990, 33, 937-942.
114. Holt, D. A.; Levy, M. A.; Yen, H.-K.; Oh, H.-J.; Metcalf, B. W.; Weir, P. J. Inhibition of Steroid 5α-Reductase by 3-Nitro steroids: Synthesis, mechanism of inhibition and in vivo activity. Bioorg. Med. Chem. Lett. 1991, 1, 27-32.
115. Holt, D. A.; Levy, M. A.; Oh, H.-J.; Metcalf, B. W. Synthesis of a Steroidal A ring aromatic sulfonic acid as an inhibitor of steroid 5α-Reductase. Steroids 1991, 56, 4-7.
116. Holt, D. A.; Levy, M. A.; Ladd, D. L.; Oh, H.-J.; Erb, J. M.; Heaslip, J. I.; Brandt, M.; Metcalf, B. W.; Yen, H.-K.; Rozamus, L. W. 3-Phosphinic Acid and 3-Phosphonic Acid Steroids as Inhibitors of Steroid 5α-reductase: Species Comparison and Mechanistic Studies. Bioorg. Chem. 1991, 19, 245-260.
117. Nakai, H.; Terashima, H.; Arai, Y. International Patent Application EP 0 291245 A2, Nov. 17, 1988; Chem. Abstr. 110, 23, 212384t.
118. Gohring, S.; Reichert, M.; Hartmann, R. W. 5α-Reductase Inhibitors: Synthesis and Structure-Activity in New Non-Steroidal Compounds. Eur. J. Pharm. Sci. 1994, 2, 101.
119. Abell, A. D.; Brandt, M.; Levy, M. A.; Holt, D. A. A Non-Steroidal Diene Acid Inhibitor of Human Type-2 Steroid 5α-reductase. Bioorg. Med. Chem. Lett. 1994, 4, 2327-2331.
120. Jones, C. D.; Audia, J. E.; Lawhorn, D. E.; McQuaid, L. A.; Neubauer, B. L.; Pike, A. J.; Pennington, P. A.; Stamm, N. A.; Toomey, R. E.; Hirsch, K. S. Nonsteroidal Inhibitors of Human Type-I Steroid 5α-Reductase. J. Med. Chem. 1993, 36, 421-423.
121. Blagg, J.; Ballard, S. A.; Cooper, K.; Finn, P. W.; Johnson, P. S.; MacIntyre, F.; Maw, G. N.; Spargo, P. L. The Development of Non-Steroidal Dual Inhibitors of Both Human 5α-Reductase Isozymes. Bioorg. Med. Chem. Lett.. 1996, 6, 1517-1522.
122. FK-143, 5α-Reductase Inhibitor Treatment of BPH. Drugs Future 1996, 21, 473-475.
123. Hirosumi, H.; Nakayama, O.; Fagan, T.; Sawada, K.; Chida, N.; Inami, M.; Takahashi, S.; Kojo, H.; Notsu, Y.; Okuhura, M. FK143, A Novel, Non-steroidal Inhibitor of Steroid 5α-Reductase: (1) In Vitro Effects on Human and Animal Prostates. J. Steroid Biochem. Mol. Biol. 1995, 52, 357-363. Hirosumi, H.; Nakayama, O.; Fagan, T.; Sawada, K.; Chida, N.; Inami, M.; Takahashi, S.; Kojo, H.; Notsu, Y.; Okuhura, M. FK143, A Novel, Non-Steroidal Inhibitor of Steroid 5α-reductase: (2) In vivo Effects on Rat and Dog Prostates. J. Steroid Biochem. Mol. Biol. 1995, 52, 365-373.
124. Hirosumi, H.; Nakayama, O.; Fagan, T.; Sawada, K.; Chida, N.; Inami, M.; Takahashi, S.; Kojo, H.; Notsu, Y.; Okuhura, M. FK143, A Novel, Non-steroidal Inhibitor of Steroid 5α-Reductase: (1) In Vitro Effects on Human and Animal Prostates. J. Steroid Biochem. Mol. Biol. 1995, 52, 357-363. Hirosumi, H.; Nakayama, O.; Fagan, T.; Sawada, K.; Chida, N.; Inami, M.; Takahashi, S.; Kojo, H.; Notsu, Y.; Okuhura, M. FK143, A Novel, Non-Steroidal Inhibitor of Steroid 5α-reductase: (2) In vivo Effects on Rat and Dog Prostates. J. Steroid Biochem. Mol. Biol. 1995, 52, 365-373.
125. Blagg, J.; Maw, G. N. Unpublished results.
126. Holt, D. A.; Yamashita, D. S.; Konialian-Beck, A. L.; Luengo, J. I.; Abell, A. D.; Bergsma, D. J.; Brandt, M.; Levy, M. A. Benzophenone and Indolecarboxylic Acids: Potent Type-2 Specific Inhibitors of Human Steroid 5α-Reductase: J. Med. Chem. 1995, 38, 13-15.
127. Bakshi, R. K.; Patel, G. F.; Rasmusson, G. H.; Baginsky, W. F.; Cimis, G.; Ellsworth, K.; Chang, B.; Bull, H.; Tolman, R. L.; Harris, G. S. 4,7β-Dimethyl-4-azacholestan-3-one (MK-386) and Related 4-Azasteroids as Selective Inhibitors of Human Type I 5α-Reductase. J. Med. Chem. 1994, 37, 3871-3784.
128. Haffner, C. Synthesis of 6-Azacholesten-3-ones: Potent Inhibitors of 5α-Reductase. Tetrahedron Lett. 1995, 36, 4039-4042.
129. LY191704, Type 1 Steroid 5α-Reductase Inhibitor, Treatment of Androgenic Alopecia. Drugs Future 1995, 20, 144-147.
130. Mook, R. A.; Lackey, K.; Bennett, C. Synthesis of Phenanthridin-3-one Derivatives: Non-Steroidal Inhibitors of Steroid 5α-Reductase. Tetrahedron Lett. 1995, 36, 3969-3972.
131. Brandt, M.; Levy, M. A.; Holt, D. A. A Comparison of Steroidal and Non-Steroidal Inhibitors of Human Steroid 5α-Reductase: New Tricyclic Aryl Acid Inhibitors of the Type-1 Isozyme. Bioorg. Med. Chem. Lett. 1996, 6, 481-484.
132. Hedlund, H.; Andersson, K.-E.; Ek, A. Effects of prazosin in patients with benign prostatic obstruction. J. Urol. 1983, 130, 275-278.
133. Eri, L. M.; Tveter, K. J. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 1995, 154, 923-934.
134. Iacovou, J. W.; Dunn, M. Indoramin-an effective new drug in the management of bladder outflow obstruction. Br. J. Urol. 1987, 60, 526-528.
135. Rittmaster, R. S.; Finasteride. N. Engl. J. Med. 1994, 330, 120-125.
136. Gormley, G. J. Finasteride: A Clinical Review. Biomed. Pharmacother. 1995, 49, 319-324.
137. McConnell, J. D. Finasteride therapy for benign prostatic hyperplasia. In Textbook of Benign Prostatic Hyperplasia; Kirby, R., McConnell, J., Fitzpatrick, J., Roehrborn, C., Boyle, P., Eds.; Isis Medical Media: Oxford, 1996; pp 260-265.
138. Montironi, R.; Valli, M.; Fabris. G. Treatment of benign prostatic hyperplasia with a 5α-reductase inhibitor: morphological changes in patients who fail to respond. J. Clin. Pathol. 1996, 49, 324-328.
139. Andersen, J. T.; Ekman, P.; Wolf, H.; Beisland, H. O.; Johansson, J. E.; Kontturi, M.; Lehtonen, T.; Tveter, K. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-controlled study. Urology 1995, 46, 631-637.
140. 1-Adrenoceptor antagonists as treatments for benign prostatic hyperplasia. Exp. Opin. Invest. Drugs 1995, 4, 915-923.
141. Eri, L. E.; Tveter, K. J. A prospective placebo-controlled study of the leuteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J. Urol. 1993, 150, 359-364.
142. Tsang, C. S.; Kong, A.; Marafelia, P.; Cunningham, G. R. Effects of fmasteride on the rat ventral prostate. J. Androl. 1993, 14, 79-86.
143. Rittmaster, R. S.; Manning, A. P.; Wright, A. S.; Thomas, L. N.; Whitefield, S.; Norman, R. W.; Lazier, C. B.; Rowden, G. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 1995, 136, 741-748.
144. Gonzalez-Barcena, D.; Vadillo-Buenfil, M.; Gomez-Orta, F.; Gareia, M. F.; Cardenas Cornejo, I.; Graef-Sanchez, A.; Comaru-Schally, A. M.; Schally, A. V.
145. Eri, L. M.; Tveter, K. J. A prospective placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J. Urol. 1993, 150, 90-94.
146. Gingell, J. C.; Konagel, H.; Kurth, K. H.; Tunn, U. W. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor, atamestane, in patients with benign prostatic hyperplasia not requiring operation. J. Urol. 1995, 154, 399-401.
147. El-Etreby, M. F.; Nishino, Y.; Habenicht, U. F.; Henderson, D. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. J. Androl. 1991, 12, 403-414.
148. Langenstroer, P.; Tang, R.; Shapiro, E.; Divish, B.; Opgenorth, P.; Lepor, H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tensionstudies. J. Urol. 1993, 149, 495-499.
149. Le Brun, G.; Moldovan, F.; Aubin, P.; Ropiquet, F.; Cussenot, O.; Fiet, J. Identification of endothelin receptors in normal and hyperplastic human prostate tissues. Prostate 1996, 28, 379-384.
150. Kobayashi, S.; Tang, R.; Wang, B.; Opgenorth, T.; Langenstroer, P.; Shapiro, E.; Lepor, H. Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol. Pharmacol. 1993, 45, 306-311.
151. Webb, M.; Chao, C.; Rizzo, M.; Shapiro, R.; Neubauer, E.; Liu, K.; Aversa, C.; Treiger, B. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction. Mol. Pharmacol. 1995, 47, 730-737.
152. Walden, P.; Ittmann, M.; Lepor, H. The endothelin axis and prostatic hyperplasia. AUA. 464A, Orlando, 1996.
153. Griffiths, K. Molecular control of prostate growth. In Textbook of Benign Prostatic Hyperplasia; Kirby, R., McConnell, J., Fitzpatrick, J., Roehrborn, C., Boyle, P., Eds.; Isis Medical Media: Oxford, 1996; pp 23-55.
154. Steiner, M. S. Review of Peptide Growth factors in Benign prostatic hyperplasia and urological malignancy. J. Urol. 1995, 153, 1085-1096.
155. Culig, Z.; Hobisch, A.; Cronauer, M. V.; Radmayr, C.; Hittmair, A.; Zhang, J.; Bartsch, G.; Klocker, H. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996, 28, 392-405.
156. Peehl, D. M.; Cohen, P.; Rosenfield, R. G. The insulin-like growth factor system in the prostate. World J. Urol. 1995, 13, 306-311.
157. Tutrone, R. F.; Ball, R. A.; Oraitz, D. M.; Leder, P.; Richie, J. P. Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J. Urol. 1993, 149, 633-639.
158. Marengo, R. S.; Chung, L. W. K. An orthotopic model for the study of growth factors in the ventral prostate of the rat: effects of epidermal growth factor and basic fibroblast growth factor. J. Androl. 1994, 15, 277-286.